Turkey has replaced its 2017 pharmaceutical pricing rules with a new framework covering external reference pricing, generic entry, biosimilars, currency adjustment and alternative reimbursement.
Poland will remove higher-cost brands from its zero-co-payment medicine lists where cheaper reimbursed equivalents can provide the same free access for eligible patients.
Denmark’s first results from a class-wide assessment pathway show how HTA bodies can shorten access timelines when repeated full appraisals add limited decision value.
The US administration has added Belgian-headquartered UCB to its MFN pricing programme, increasing the direct link between US launch prices and pricing decisions in other developed markets.
NICE has adopted the new UK EQ-5D-5L value set, changing the utility values used in cost-effectiveness assessment with differing effects across types of medicines.
Germany’s health and economic ministries have convened an expert panel to develop further exemptions from the additional 8.5% manufacturer rebate due from January 2027.
A one-month Bulgarian consultation has proposed tighter prescribing, procurement and expenditure-monitoring rules for medicines supplied through exceptional access routes.
A Swiss parliamentary committee wants planned medicines-pricing reforms rewritten as industry reports that US MFN considerations are already leading companies to withhold Swiss reimbursement and regulatory submissions.
Norway is developing managed-entry agreements for medicines that may be cost-effective for individual patients but create unaffordable or highly uncertain expenditure when used across large eligible populations.
EU regulators have moved major pre-submission activities into EMA's IRIS platform while linking the same workflow to early identification and preparation of mandatory Joint Clinical Assessments.
Serbia has reduced patient co-payments across 769 prescription medicines and extended subsidised access to further therapies as part of a wider affordability package.
The UK medicines regulator is proposing higher charges for selected services in return for guaranteed assessment timelines and partial fee rebates when those guarantees are missed.
Spain’s competition authority has called for changes to proposed medicine pricing rules covering discounts, distribution margins, notified prices and the new dynamic-pricing system.
Germany’s statutory health insurance association has confirmed that new nationwide prescribing protections can no longer be agreed through AMNOG reimbursement agreements following the July GKV law.
A federal audit estimates that most purchasing benefits granted to Swiss pharmacies, practices and hospitals are not reaching insurers or patients, and raises lower regulated medicine prices as a possible alternative.
Belgium has converted a temporary €80.4 million industry payment into a permanent annual charge, adding it to existing turnover levies and a separate clawback for medicines-budget overspending.
France will reduce the minimum wholesale margin on low-priced reimbursed medicines while increasing the additional payment for products requiring refrigerated distribution.
Bulgaria has narrowed its pharmaceutical expenditure-overrun mechanism to reference medicines and specified combination products, while introducing a new formula for allocating excess spending among companies that remain within the scheme.
